Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart surgery sedative may cut confusion risk, massive study hints

NCT ID NCT07249164

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

This study analyzed health records from over 400,000 adults who had heart surgery to see if the sedative dexmedetomidine helped prevent problems like confusion, kidney injury, or death within 30 days. Researchers compared patients who received the drug around surgery time to those who did not. The goal is to find better ways to manage sedation during routine heart surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

343,112 people

The number who actually took part.

Started

Jan 2010

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients in the TriNetX Global Collaborative Network meeting the full CABG or valve eligibility criteria during 1 January 2010 through 1 July 2025 form the study population before propensity-score matching. CABG is primary and valve exploratory, with separate procedure anchors and matching. Age at Event is 18-100 years, subject to platform privacy restrictions, with the same five-domain HCO filter. The 9 September 2026 counts were 235,752 CABG, 139,542 valve and 32,182 meeting both complete definitions. Enrollment is the overlap-adjusted platform total: 235,752 + 139,542 - 32,182 = 343,112. This is a derived count from sequential LIVE queries, not a certified fixed-time snapshot or independently verified cross-HCO person deduplication. Matched and endpoint denominators are reported separately; effects are not pooled.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * A qualifying CABG-coded procedure for the primary analysis, or a qualifying valve-coded procedure for the separate exploratory analysis, during 1 January 2010 through 1 July 2025. * Age at Event 18-100 at a qualifying procedure, subject to the platform's additional age-related privacy restrictions. * A procedure-date index defined by the first qualifying procedure within the clinical period after the date and age filters, with the same eligibility logic in both exposure groups within each procedure population. * Data contributed by healthcare organisations providing demographics, diagnoses, procedures, medications and laboratory domains. * Medication-record status classified using RxNorm 48937 during days -1 through 0 relative to the qualifying index procedure. Exclusion Criteria: * An ESRD or dialysis record during days -90 through -1: ICD-10-CM N18.6, Z49 or Z99.2; SNOMED CT 265764009; ICD-10-PCS 5A1D60Z or 5A1D00Z; or ICD-9-CM 39.95. * Any R41.0 or F05 record on or before day 0 in all available prior history relative to the index procedure, applied before matching in both the CABG-coded and valve-coded populations. Primary, secondary, F05-only and encounter endpoints retain this eligibility definition. Native matching is repeated within each outcome batch, and identical matched patients across batches are not established. Some eligibility records may occur after the exposure window begins on day -1, which may introduce selection or collider bias despite application before matching. The study does not require continuous preoperative observation, complete 30-day follow-up or survival to a landmark. Missing laboratory measurements do not automatically exclude a patient. The available aggregate outputs do not permit clinical adjudication of individual procedures or confirmation that surgery is first-ever or isolated.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac surgical procedures are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • China Medical University Hospital

    Taichung, Taichung City, 40447, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.